{'fraction_non_alphanumeric': 0.027079303675048357, 'fraction_numerical': 0.017408123791102514, 'mean_word_length': 5.317073170731708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
DDAVP IN CHILDHOOD NOCTURNAL ENURESIS

ABSTRACT. A double‐blind study of 18 children aged 6–12 years suffering from primary nocturnal enuresis without signs of underlying organic disease is reported. 20 μg of DDAVP (desamino‐d‐arginine vasopressin, Minirin®) was given intranasally at bedtime. The effect was prompt and satisfactory in 8 children and relatively good in another 8 children. No adverse effects were noted. DDAVP is advocated for temporary use in children with nocturnal enuresis needing immediate help.